Increasing numbers of successful pregnancies are reported in recipients of allogeneic hemopoietic stem cell transplantation (HSCT). These may occur naturally, or more commonly, through assisted reproduction. The pregnancy outcomes are usually normal. There are currently no guidelines on the prenatal management of pregnancies involving HSCT recipients. HSCT recipients are unique in that their red cells, lymphocytes and even the DNA in the circulation are donor derived. As a result, typical prenatal screening tests in parents, including mean cell volume (MCV), hemoglobin pattern, blood group, infective serology and DNA screening, are all affected. The MCV cannot be used as guide for iron and folate supplements, or for thalassemia and sickle cell anemia screening. Such screening must be based on pre-HSCT indices and pre-HSCT DNA samples. The risks for hemolytic disease of newborn and hepatitis B virus transmission have to be re-evaluated, based on both preand post-HSCT patient as well as donor blood group and serology results. Good communication between obstetricians and the HSCT physician is paramount to promote successful pregnancies in this distinct patient population.
Introduction
Most recipients of allogeneic hematopoietic stem cell transplantation (HSCT) suffer from secondary infertility owing to gonadal damage from myeloablative conditioning. However, the use of non-total body irradiation and non-ablative protocols means that some patients may preserve their fertility, especially in males. 1 Improved prognosis and reduced morbidity may also increase patients' desire and ability to start or expand a family. Hence, the number of pregnancies involving HSCT recipients is increasing. 2, 3 Similar to other organ transplant recipients, pregnant HSCT survivors face issues such as fetal exposure to immunosuppression and the possibility of pregnancy-related disease recurrence. 4 The chance of conception and the course of pregnancy is also hampered by HSCT-related organ damage and graft versus host disease. However, more importantly and unique to the HSCT scenario, the blood and immune system of the host are replaced by that of an allogeneic donor. Therefore, pregnancies in which either the mother or father is an HSCT recipient present unique challenges and must be carefully monitored.
Planning for pregnancy
As in the general population, a successful delivery is more likely with a planned pregnancy. 5 Planning may predate HSCT. Fertility advice and gamete preservation is increasingly offered to young patients receiving chemotherapy, well before the decision of HSCT. 6, 7 The issues of leukemic contamination, treatment delay, chemotherapy exposure of gametes and fate of cryopreserved tissues have to be discussed. 6 Nevertheless, before further myeloablation and gonadal damage, gamete preservation should be revisited at HSCT referral and evaluation. Options included cryopreservation of sperms, oozytes, 8 pre-fertilized embryos or even gonadal tissues. 9 For HSCT recipients failing natural conception, the use of in vitro fertilization (IVF) or even intracytoplasmic sperm injection, 10 using concentrated/ cryopreserved/donor sperm and oocytes may be considered. The use of IVF allows earlier dating and monitoring of pregnancy. 11 For HSCT recipients transplanted for familial metabolic defects or thalassemia, there may be a role during IVF for pre-implantation genetic diagnosis in the choice of embryo for cryoprerservation or implantation. 12 This eliminates the need for prenatal diagnosis and potential therapeutic abortion later on (see below).
All couples of reproductive age contemplating starting a family and involved in HSCT are encouraged to consult a gynecologist before and after HSCT to maximize the chance of a successful pregnancy. Once a positive pregnancy test is confirmed, the pregnant mother is enrolled into prenatal care. The routine prenatal screening process varies from country to country owing to local genetic and infective concerns. However, the basic components of prenatal screening are essentially the same in most of the developed countries and are outlined in Table 1 .
Hematological tests
A complete blood picture (CBP) is requested for all pregnant mothers to screen for anemia and thrombocytopenia. The hemoglobin (Hb) and platelet (Plt) levels of stable HSCT recipients (both autologous and allogeneic) are lower than that in general population. 13 These may undergo further physiological decline during pregnancy, and should be carefully monitored. Their MCV can also be spuriously high for red cells produced from engrafted marrow, making microcytosis an unreliable screen for thalassemia and iron deficiency, and macrocytosis unreliable for folate deficiency. 15 Direct assessments of ferritin, transferrin saturation and red cell folate levels may be needed. Iron and folate supplements are issued to most pregnant mothers. Iron supplements may not be necessary in HSCT recipients, who have iron overload from previous transfusions, 14 although folate supplement is probably prudent. For thalassemia and sickle cell anemia prenatal screening, it is also irrelevant to assess the MCV and hemoglobin pattern from either the mother or her partner who are HSCT recipients. Decisions on the need for DNA screening has to be based on pre-HSCT MCV and hemoglobin pattern results. Furthermore, the current peripheral blood DNA represent donor DNA, and not the host gametal DNA that is passed on to the offspring. Hence, archival DNA or alternative DNA sources (e.g. mouth washing, biopsy samples and family members) may be considered as reference for thalassemia and sickle cell mutation detection.
Red cell blood group typing and antibody screening are performed for all pregnant mothers and are often repeated pre-term. This prepares for potential maternal transfusion and prevents hemolytic disease of the newborn (HDN). Published guidelines for post-HSCT transfusion are applicable to post-HSCT pregnancy-related transfusion needs, and the use of irradiated blood products may be prudent. 16, 17 However, for HDN, previous pre-HSCT pregnancy history cannot predict the risk. This is because both the red cell and immune system of the pregnant HSCT recipient have switched to that of host origin. For ABO blood group, there will be a higher incidence of ABO mismatch between mother and fetus. However, ABO isohemagglutin seldom cause severe HDN and titers are often low after HSCT. 18 For the Rhesus (Rh) blood group, RhD negative (Àve) recipients receiving RhD-positive ( þ ve) allografts are no longer at risk for HDN. However, vice versa, RhDÀve graft recipients have an acquired risk. Fortunately, titers of post-HSCT anti-D alloantibodies are usually low. 16 Likewise, for RhDÀve recipients of RhDÀve grafts, alloimmunization rate by RhD þ ve blood products is below 10%. 19 In both cases, however, it is uncertain whether the anti-D titer may increase during amenestic exposure during post-HSCT pregnancy and frequent monitoring may be prudent.
Serological tests
Serological screening for infective agents protects the fetus from potentially treatable serologically transmissible diseases and also detects fetuses at increased risk of malformation. For HSCT recipients, with their extensive risk of exposure to potential transfusion-related pathogens, such tests are of heightened significance. For Venereal Disease Research Laboratory test (VDRL) and rubella serology, the replacement by the donor immune system may eradicate previous host memory of exposure to such disease and vaccines. Furthermore, lasting passive transfer of antibody or immunity from the donor does not occur. 20 Most HSCT recipients are revaccinated for rubella, and the seropositive rates should be around 95%. 21 For VDRL, false-positive and false-negative testing after HSCT are both possible, owing to HSCT-related autoantibodies and immunocompromise, respectively. The use of multiple antitreponema detection assays may be prudent for prenatal screening. 22 False-negative HIV and HTLV-1 testing have not been reported post-HSCT. 23 Infective serology screens are mandatory in both donor and recipient before HSCT, and the records should be consulted.
Hepatitis B virus (HBV) is endemic (10% carriers) in the Far East and newborns are universally vaccinated. For mothers who are HBV surface antigen (HBsAg) carriers, hyperactive HBV immunoglobulin (HBIG) is also given to the baby at birth. 24 During HSCT, HBV-related complications are minimized by lamivudine prophylaxis. Indeed, the HBsAg carrier status may be eradicated after HSCT by donor immunity. 25 This eradication is reversible, and patients may lose their acquired HBs antibody (Ab) and revert back to HBsAg positivity. Significant levels of circulating HBV DNA can still be detected intermittently. Hence, the HBsAg status at antenatal screening is not a complete assessment of HBV risk to the fetus. The exact pre-HSCT HBV status of the patient has to be verified from records. It is uncertain whether successful adoptive immunotransfer and seroconversion in previous HBVpositive pregnant HSCT recipients give adequate protection to the fetus. As intermittent viremia may still occur, HBIG administration is probably prudent. Finally, as alpha fetal protein level (AFP) is used for neural tube defect screening, it must be remembered that in HBV carriers, the risk of hepatocellular carcinoma may be increased after HSCT, and can cause raised AFP. 26 
Genetic testing
In many parts of the world, population screening and genetic testing are in place to identify fetus at risk for hereditary diseases. These included thalassemia alpha and beta in South-East Asia and Mediteranean populations and sickle cell disease in African descendants. Genetic testing is also available for families with known hereditary diseases, such as Tay Sachs and cystic fibrosis. For genetic tests based on fetal sample from amniocentesis or chorionic villi sampling (CVS), previous HSCT in the pregnant mother does not pose a problem. Indeed, for HSCT recipients, maternal blood contamination becomes less of an issue for amniocentesis and CVS, as the maternal blood comes from a donor who is usually not directly related to the fetus. 27 However, when linkage analysis is performed using parental blood samples from HSCT recipients, it is of paramount importance to realize that peripheral blood DNA comes from the donor. Hence, archival DNA/blood material or alternative biopsy (e.g. skin fibroblasts) may be needed. The most significant pitfall lies in thalassemia and sickle cell screening programs, when genetic screening may not even be initiated by the unsuspecting and uninformed obstetrician, owing to the apparent normal (donor derived) CBP in the HSCT recipient father or mother. Hence, all HSCT recipients are encouraged to volunteer such history to their obstetricians or visit a prenatal center that has access to advice from transplant experts.
Conclusions
Pregnancy after HSCT is still relatively uncommon. Normal full-term delivery is the most likely outcome, although special precautions are needed in prenatal management to optimize fetal outcome. Assisted reproduction is increasingly available for future HSCT recipient couples. Hence, for HSCT recipients of reproductive age, it would be advisable to keep a record of full red cell phenotype, CBP, infective serology and medical records of both the patient and donor for future obstetric references. The patients should also be informed to volunteer for appropriate thalassaemia/sickle screening/other genetic tests in future pregnancies. As DNA from transplanted blood is not useful for genetic tests, a different source would be necessary. Finally, for pregnant HSCT recipients, routine iron tablets may be unnecessary, and ferritin and transferrin saturation would be more useful than the MCV to assess for potential iron deficiency.
